C-BREEZE 1: Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection

Press/Media: Press / Media

PeriodNov 29 2017

Media coverage

1

Media coverage

  • TitleC-BREEZE 1: Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection
    Media name/outletNational AIDS Treatment Advocacy Project
    CountryUnited States
    Date11/29/17
    PersonsFred Poordad, Eric J Lawitz